Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576830 | 0.82 | LMNA (0.50) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL29889744 | 0.81 | LMNA (0.49) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL20498296 | 0.81 | LMNA (0.49) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL21811082 | 0.79 | LMNA (0.55) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL30931955 | 0.79 | LMNA (0.55) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL21811071 | 0.78 | LMNA (0.54) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL446754 | 0.78 | NPC1 (0.41) | LMNAC1SPOLBTDP1MEN1 | |
| SCHEMBL16166903 | 0.77 | C1S (0.44) | LMNAC1SL3MBTL1TDP1MEN1 | |
| SCHEMBL14485028 | 0.77 | LMNA (0.51) | LMNACSNK1ECCNT1CCNA2CDK2 | |
| SCHEMBL3573674 | 0.75 | LMNA (0.50) | LMNACSNK1ECCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-111247136-A | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating diseases and disorders associated with IRE1 | 吉宁特有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | LMNA 637/4885CSNK1E 101/4885C1S 877/4885 |
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | LMNA 1829/4885CSNK1E 675/4885C1S 1040/4885 |
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | LMNA 3974/4885CSNK1E 217/4885C1S 3468/4885 |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | XBP1, ERN1, ATF4 | LMNA 651/4885CSNK1E 291/4885C1S 4835/4885 |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | XBP1, ERN1, ATF4 | LMNA 651/4885CSNK1E 291/4885C1S 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.